シンフィブラート、シンフィブレート
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2012/09/12 16:52:28」(JST)
[Wiki en表示]
Simfibrate
|
Systematic (IUPAC) name |
propane-1,3-diyl bis[2-(4-chlorophenoxy)-2-methylpropanoate] |
Clinical data |
Pregnancy cat. |
? |
Legal status |
? |
Identifiers |
ATC code |
C10AB06 |
PubChem |
CID 5217 |
ChemSpider |
5028 Y |
UNII |
L2R75RQX26 Y |
KEGG |
D01212 Y |
Synonyms |
3-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}propyl 2-(4-chlorophenoxy)-2-methylpropanoate |
Chemical data |
Formula |
C23H26Cl2O6 |
Mol. mass |
469.354 g/mol |
SMILES
- Clc2ccc(OC(C(=O)OCCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)(C)C)cc2
|
InChI
-
InChI=1S/C23H26Cl2O6/c1-22(2,30-18-10-6-16(24)7-11-18)20(26)28-14-5-15-29-21(27)23(3,4)31-19-12-8-17(25)9-13-19/h6-13H,5,14-15H2,1-4H3 Y
Key:JLRNKCZRCMIVKA-UHFFFAOYSA-N Y
|
Y (what is this?) (verify)
|
Simfibrate is a fibrate.
Lipid modifying agents (C10)
|
|
GI tract |
Cholesterol absorption inhibitors, NPC1L1
|
|
|
Bile acid sequestrants/resins (LDL)
|
- Cholestyramine
- Colestipol
- Colestilan
- Colextran
- Colesevelam
|
|
|
Liver |
Statins (HMG-CoA reductase, LDL)
|
- Simvastatin#
- Atorvastatin
- Fluvastatin
- Lovastatin
- Mevastatin
- Pitavastatin
- Pravastatin
- Rosuvastatin
- Cerivastatin‡
|
|
Niacin and derivatives (HDL and LDL)
|
- Niceritrol
- Niacin
- Nicofuranose
- Aluminium nicotinate
- Nicotinyl alcohol
- Acipimox
|
|
|
Blood vessels |
Fibrates (PPAR)
|
- Clofibrate‡
- Bezafibrate
- Aluminium clofibrate
- Gemfibrozil
- Fenofibrate
- Simfibrate
- Ronifibrate
- Ciprofibrate
- Etofibrate
- Clofibride
- Clinofibrate
|
|
CETP inhibitors (HDL)
|
- Anacetrapib†
- Dalcetrapib§
- Evacetrapib§
- Torcetrapib§
|
|
|
Combinations |
- Niacin/lovastatin
- Niacin/simvastatin
- Ezetimibe/simvastatin
- Niacin/laropiprant
|
|
Other |
- Dextrothyroxine
- Probucol
- Tiadenol
- Benfluorex
- Meglutol
- Omega-3-triglycerides
- Magnesium pyridoxal 5-phosphate glutamate
- Policosanol
- Lapaquistat§
- Mipomersen
- Alipogene tiparvovec
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m
|
k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon
|
m(A16/C10),i(k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)
|
|
|
|
English Journal
- Response to: Laparoscopic cholecystectomy is safe and effective for the treatment of biliary dyskinesia in the pediatric population.
- Richmond BK.
- The American surgeon.Am Surg.2010 Dec;76(12):1426.
- PMID 21265362
- Influence of fibrates on ethanol metabolism in rats.
- Hayashi K1.
- Nihon Arukōru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence.Nihon Arukoru Yakubutsu Igakkai Zasshi.2000 Oct;35(5):306-20.
- The fibrates are widely used for the reduction of high triglyceride levels. The fibrates act as the peroxisome proliferator-activated receptor alpha ligands to regulate the transcription of large number of genes that affect lipoprotein and fatty acid metabolism. The male rats of Wistar strain, simfi
- PMID 11144151
- The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats.
- Hattori T1, Nagamatsu T, Ito M, Suzuki Y.
- Japanese journal of pharmacology.Jpn J Pharmacol.1996 Jan;70(1):25-33.
- The possibility that hyperlipidemia and an increase of mononuclear cells in the glomeruli could participate in the pathogenesis of minimal change glomerulopathy was evaluated in puromycin aminonucleoside (PAN) nephrosis in rats. Significant increases in intraglomerular CD4-, IL-2-receptor (R)- and E
- PMID 8822086
Japanese Journal
- 武 信昭,平野 哲哉,伊与田 修,末永 義則
- 西日本皮膚科 50(6), 1018-1021, 1988
- 66才女子。約10年来の尋常性乾癬が昭和62年の春頃より悪化した。7月頃高血圧を指摘されシンフィブラートの内服を開始した。9月になつて四肢に緊満性水疱が出現し, 水疱性類天疱瘡の疑いで入院となる。検査成績で赤沈亢進, 好酸球増多, IgE高値を示した。病理組織学的所見で表皮真皮間の裂隙とその直下の好酸球, 小円形細胞の浸潤があつた。蛍光抗体直接法で基底膜部にC3の沈着があつた。血清の抗基底膜抗体価 …
- NAID 130004473375
- じん血管性高血圧症および閉そく性動脈硬化症を合併したアポE3欠損症(E2/2phenotype)の1例
- 焦 昇,垂井 清一郎,野崎 秀一,原 斉,中島 忠久,亀田 芳,久保 正治,徳永 勝人,広部 一彦,松沢 佑次
- 日本内科学会雑誌 73(12), 1805-1810, 1984
- … の増加を認め, III型高脂血症と診断された.等電点電気泳動によるアポEの分析ではE2/2 phenotypeを示し,アポE<sub>3</sub>の欠損が確認された.入院後,低カロリー(1400Cal/日),低脂肪食(20g/日)の食事療法およびsimfibrateとniceritrolによる薬物療法により高脂血症は改善され,間歇性跛行も軽快した.以上より全身性動脈硬化性疾患,殊に腎血管性高血圧症を呈する疾患の中にアポE<sub>3</sub>欠損によるIII型高脂血症を原因 …
- NAID 130000891397
★リンクテーブル★
[★]
- 英
- simfibrate
- 関
- シンフィブレート
[★]
- 英
- simfibrate
- 関
- シンフィブラート